Description

We are a pharmaceutical company focused on the research and development of new immunotherapeutic products with the purpose of presenting new compounds that treat diseases related to TGF-beta signaling dysfunction. We focus on the early discovery of novel therapeutic products that modulate the immune system, to obtain new treatments against diseases with an important immuno-inflammatory component such as cancer and fibrosis.

Our mission is the discovery and development of the next generation of therapeutic products for the treatment of serious diseases related to TGF-beta signaling and our vision is to improve the quality of life and ultimately contribute to the cure of people suffering from these devastating diseases. We are currently focusing our efforts on the development of TGF-beta inhibitors with gastrointestinal properties for the treatment of colon cancer and Crohn’s disease.

Areas/Lines R+D+i

Drug discovery

Therapeutic target TGF-beta

Immunomodulators

Cancer

Fibrosis

Most outstanding R+D+i projects

TGF-beta inhibitor with properties restricted to the gastrointestinal tract for the treatment of colon cancer

Contact

E-mail: info@origobiopharma.com